Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 6/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29851417 | 1.00 | MAPT (0.64) | MAPTKMT2AMEN1LMNAHTT | |
| SCHEMBL17597185 | 0.89 | MAPT (0.64) | MAPTKMT2AMEN1LMNAHTT | |
| SCHEMBL3021071 | 0.87 | LMNA (0.64) | MAPTKMT2AMEN1LMNAHTT | |
| SCHEMBL16198146 | 0.84 | LMNA (0.57) | MAPTKMT2AMEN1LMNAHTT | |
| SCHEMBL2030261 | 0.83 | LMNA (0.59) | MAPTKMT2AMEN1LMNAHTT | |
| SCHEMBL30166997 | 0.83 | ALDH1A1 (0.60) | MAPTKMT2AMEN1LMNAHTT | |
| SCHEMBL30072571 | 0.82 | HSD17B10 (0.52) | MAPTKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL443483 | 0.82 | HSD17B10 (0.52) | MAPTKMT2AMEN1HTTALDH1A1 | |
| SCHEMBL13548665 | 0.81 | LMNA (0.47) | MAPTKMT2AMEN1LMNAHTT | |
| SCHEMBL29115634 | 0.81 | LMNA (0.57) | MAPTKMT2AMEN1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383914-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-21 | — | — | US | disclosed |
| US-12065446-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-20 | — | — | US | disclosed |
| US-20230097422-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-30 | — | — | US | disclosed |
| CN-113121562-B | Polycyclic compounds as inhibitors of bruton's tyrosine kinase | 詹森药业有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-11319329-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| CN-113121562-A | Polycyclic compounds as inhibitors of bruton's tyrosine kinase | 詹森药业有限公司 | 2021-07-16 | — | — | CN | disclosed |
| US-20210101910-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-08 | — | — | US | disclosed |
| US-10934310-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-02 | — | — | US | disclosed |
| EP-3719022-A1 | POLYCYCLIC COMPOUNDS AS INHIBITORS OF BRUTON'S TYROSINE KINASE | Janssen Pharmaceutica NV (BE) | 2020-10-07 | — | — | EP | disclosed |
| US-10717745-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-21 | — | — | US | disclosed |
| US-8044090-B2 | N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY (US) | 2011-10-25 | — | — | US | disclosed |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2009-12-10 | — | — | US | disclosed |
| EP-1859798-A1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2007-11-28 | — | — | EP | disclosed |
| EP-1379239-B1 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | LILLY CO ELI (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | CHEN ZHAOGEN | 2007-05-03 | — | — | US | disclosed |
| US-7157488-B2 | N-(2-Arylethyl) benzylamines as antagonists of the 5-HT6 receptor | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | CHEN ZHAOGEN | 2006-01-12 | — | — | US | disclosed |
| US-5637593-A | MIGRAINE; HYPOTENSIVE AGENTS | SMITHKLINE BEECHAM PLC (GB) | 1997-06-10 | — | — | US | disclosed |
| EP-0674619-A1 | TRYPTAMINE ANALOGUES AS 5-HT 1?-LIKE AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994014770-A1 | TRYPTAMINE ANALOGUES AS 5-HT1-LIKE AGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10934310-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | MAPT 4231/4885KMT2A 2295/4885MEN1 2524/4885 |
| US-12065446-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | MAPT 4231/4885KMT2A 2295/4885MEN1 2524/4885 |
| US-20060009511-A9 | N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor | HTR6, HTR2C, HTR1B | MAPT 3701/4885KMT2A 1269/4885MEN1 1889/4885 |
| US-20240383914-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | ABL1, BTK, MYLK2 | MAPT 4259/4885KMT2A 2194/4885MEN1 2475/4885 |
| US-20090306110-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | MAPT 3701/4885KMT2A 1269/4885MEN1 1889/4885 |
| US-20230097422-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, LYN | MAPT 4231/4885KMT2A 2295/4885MEN1 2524/4885 |
| US-10717745-B2 | Inhibitors of Bruton's tyrosine kinase and method of their use | ABL1, BTK, LYN | MAPT 4231/4885KMT2A 2295/4885MEN1 2524/4885 |
| US-20210101910-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | ABL1, BTK, MYLK2 | MAPT 4259/4885KMT2A 2194/4885MEN1 2475/4885 |
| US-11319329-B2 | Inhibitors of Bruton's tyrosine kinase and methods of their use | ABL1, BTK, MYLK2 | MAPT 4259/4885KMT2A 2194/4885MEN1 2475/4885 |
| US-20070099909-A1 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | HTR6, HTR2C, HTR1B | MAPT 3701/4885KMT2A 1269/4885MEN1 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.